Everolimus News and Research

RSS

Abbott receives CE Mark for newest generation of drug-eluting XIENCE coronary stent system

Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

31 Oct 2017

Lab-grown miniature blood vessels mimic rare Hutchinson-Gilford Progeria Syndrome

Biomedical engineers have grown miniature human blood vessels that exhibit many of the symptoms and drug reactions associated with Hutchinson-Gilford Progeria Syndrome -- an extremely rare genetic disease that causes symptoms resembling accelerated aging in children.

16 Aug 2017

Novartis to collaborate with IBM Watson Health for improving outcomes in advanced breast cancer

Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.

5 Jun 2017

Liver transplant patients who take new anti-rejection drug gain less weight, study finds

Researchers have discovered that a new anti-rejection drug that is gentler on the kidneys after liver transplant also reduces weight gain, which is common after surgery and can lead to serious complications for transplant patients.

3 May 2017

Stents can be as effective as surgery for many patients with left main coronary artery disease

A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary artery.

1 Nov 2016

ATS releases new clinical practice guidelines for diagnosis, management of LAM

The American Thoracic Society and the Japanese Respiratory Society have published new clinical practice guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of child-bearing age.

15 Sep 2016

New generation drug eluting stents show lower efficacy than contemporary BMS, study shows

New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date.

30 Aug 2016

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy.

11 Aug 2016

FDA approves Absorb GT1 BVS to treat coronary artery disease

The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease.

5 Jul 2016

Neoadjuvant endocrine therapy 'a reasonable option' for ER-positive breast cancer

Endocrine therapy should be reconsidered as a potential option in the neoadjuvant setting for localised oestrogen receptor-positive breast cancer, say the authors of a meta-analysis.

1 Jul 2016

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.

30 Jun 2016

Everolimus-eluting bioresorbable vascular scaffold shows promise in PAD

A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.

23 Jun 2016

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.

18 Jun 2016

Post PCI symmetry important for good clinical outcome

Postprocedural asymmetry following percutaneous coronary intervention is associated with an increased risk of adverse clinical outcome, particularly in patients with suboptimal expansion, researchers report.

9 Jun 2016

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology.

6 Jun 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.

11 Mar 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

22 Jan 2016

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015